We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

58 hedge funds and large institutions have $29.4M invested in Neos Therapeutics, Inc in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more call options, than puts

Call options by funds: $3K | Put options by funds: $2K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

8% less funds holding

Funds holding: 6358 (-5)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

59% less capital invested

Capital invested by funds: $71.2M → $29.4M (-$41.8M)

Holders
58
Holders Change
-5
Holders Change %
-7.94%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
17
Reduced
17
Closed
15
Calls
$3K
Puts
$2K
Net Calls
+$1K
Net Calls Change
+$16K
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$6.41M +$845K +459,510 +10%
NCM
2
Nantahala Capital Management
Connecticut
$5.95M +$230K +125,000 +3%
SFM
3
Sphera Funds Management
Israel
$4.79M +$2.78M +1,509,757 +69%
Goldman Sachs
4
Goldman Sachs
New York
$3.15M +$2.22M +1,207,167 +98%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.58M -$87.6K -47,633 -2%
BlackRock
6
BlackRock
New York
$684K -$3.94M -2,139,233 -80%
Northern Trust
7
Northern Trust
Illinois
$640K -$59.2K -32,181 -6%
Millennium Management
8
Millennium Management
New York
$574K +$223K +121,215 +37%
Morgan Stanley
9
Morgan Stanley
New York
$539K +$216K +117,678 +39%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$460K -$213K -115,956 -25%
DM
11
Deerfield Management
New York
$414K -$2.72M -1,478,148 -82%
AIM
12
Alambic Investment Management
California
$283K +$381K +206,990 +1,711%
PP
13
Paloma Partners
Connecticut
$275K +$392K +213,200 New
PCM
14
Proxima Capital Management
New York
$266K
JP Morgan Chase
15
JP Morgan Chase
New York
$261K +$376K +204,481 +1,791%
Jane Street
16
Jane Street
New York
$213K +$234K +127,202 +332%
Renaissance Technologies
17
Renaissance Technologies
New York
$183K +$63.6K +34,587 +32%
BCM
18
Bridgeway Capital Management
Texas
$181K
SIM
19
Spark Investment Management
New York
$150K -$344K -186,958 -62%
OAM
20
Oxford Asset Management
United Kingdom
$135K +$109K +59,135 +129%
BGIM
21
Brandywine Global Investment Management
Pennsylvania
$123K +$57.1K +31,029 +48%
AG
22
Algert Global
California
$100K +$143K +77,845 New
Wells Fargo
23
Wells Fargo
California
$96K -$36.7K -19,940 -21%
WA
24
Wealthstar Advisors
Texas
$95K
Citigroup
25
Citigroup
New York
$82K +$3.2K +1,738 +3%

NEOS Hedge Fund Activity: Q2 2019 in Review

58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q2 2019, worth a combined $29.4M — down 59% from $71.2M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of NEOS and 12 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 17 added.

The largest buyer was Sphera Funds Management, adding an estimated $2.78M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.29M sold.

  • 58 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q2 2019, down from 63 in Q1 2019.
  • Funds reported $29.4M of Neos Therapeutics, Inc stock for Q2 2019, down 59% quarter-over-quarter.
  • 12 funds opened new Neos Therapeutics, Inc positions in Q2 2019 and 15 closed out, a net change of -3 holders.
  • The largest Neos Therapeutics, Inc buyer in Q2 2019 was Sphera Funds Management, an estimated $2.78M added.
  • The largest Neos Therapeutics, Inc seller in Q2 2019 was Franklin Resources, an estimated $5.29M sold.

Based on aggregated 13F filings for Q2 2019.